FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308398712> ?p ?o ?g. }

• W4308398712 abstract "<h3>Background</h3> Healthy adult peripheral blood natural killer (PBNK) cells are mature cytotoxic innate lymphocytes possessing an inherent capacity for tumor cell killing, making them attractive candidates for adoptive cell therapy. These NK cells are also amenable to chimeric antigen receptor (CAR) genomic engineering for enhanced functions. Moreover, NK cells possess an inherent capacity for off-the-shelf therapy since they are not known to cause graft-versus-host disease, unlike T cells. Approved CAR cell therapies are custom-made from each patient’s own T cells, a process that can limit patient eligibility and contribute to product variability. In this study, we compare PBNK cells to umbilical cord blood NK (CBNK) cells to evaluate both as candidate starting materials for clinical and commercial supply of CAR NK cells. <h3>Methods</h3> PBNK and CBNK cells were expanded using either a 14-day protocol and a single stimulation with Nkarta’s NKSTIM cell line plus IL-2, or with 5 stimulations over 70 days.¹ IL-12 and IL-18 were added at the beginning and end of the 70-day expansion to drive memory-like NK cell differentiation. We transduced NK cells to express CD19-targeted CAR and membrane-bound IL-15 following the first NKSTIM pulse. We measured cytotoxicity against 3 tumor cell lines by IncuCyte, and phenotyped cells for NK markers including differentiation markers CD57 and NKG2C, and NKG2A and KIR. <h3>Results</h3> Purified NK cells from 1 PBNK donor and 4 CBNK donors were successfully expanded and engineered to express high levels of CAR. The 70-day final product (FP) CBNK cells were CD57^-KIR^lo/- and NKG2A⁺, consistent with an immature phenotype, whereas the FP PBNK cells were educated, at more than 80% NKG2A^-KIR⁺. CBNK cells expanded to approximately 11-million-fold, whereas PBNK cells surpassed 250-billion-fold expansion, without appearing to have reached a terminal expansion limit. At the end of the study, Nkarta’s standard 14-day process (SP) cells [1], and FP PBNK cells were as potent or trended towards greater potency than CBNK cells against 3 different tumor targets in a 72-hour IncuCyte assay. Furthermore, FP PBNK cells were as or more potent than SP PBNK cells, depending on the tumor target. <h3>Conclusions</h3> We demonstrate healthy donor-derived PBNK cells can expand over 250 billion-fold while maintaining potency. These results show robust expansion capability of educated, potent NK cells and provide a rationale for the development of off-the-shelf CAR NK cell therapies using NK cells from donors selected to provide optimal product characteristics. <h3>Reference</h3> Whang M, Xie M, Jamboretz K, Lamar H, Guo C, Rahman N, Chan I, Whiteley E, Brandenberger R, Lazetic S, Trager J. 151 Potentiating the large-scale expansion and engineering of peripheral blood-derived CAR NK Cells for off-the-shelf application. <i>J Immunother Cancer</i>. 2021; <b>9</b>: 151." @default.
• W4308398712 created "2022-11-11" @default.
• W4308398712 creator A5007756951 @default.
• W4308398712 creator A5020244649 @default.
• W4308398712 creator A5023821463 @default.
• W4308398712 creator A5033930430 @default.
• W4308398712 creator A5037556478 @default.
• W4308398712 creator A5044519846 @default.
• W4308398712 creator A5044693959 @default.
• W4308398712 creator A5054594421 @default.
• W4308398712 creator A5058952921 @default.
• W4308398712 creator A5070576137 @default.
• W4308398712 creator A5084572579 @default.
• W4308398712 creator A5084743693 @default.
• W4308398712 date "2022-11-01" @default.
• W4308398712 modified "2023-09-25" @default.
• W4308398712 title "381 Large-scale expansion and engineering of human NK cells sourced from peripheral blood versus umbilical cord blood" @default.
• W4308398712 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0381" @default.
• W4308398712 hasPublicationYear "2022" @default.
• W4308398712 type Work @default.
• W4308398712 citedByCount "0" @default.
• W4308398712 crossrefType "proceedings-article" @default.
• W4308398712 hasAuthorship W4308398712A5007756951 @default.
• W4308398712 hasAuthorship W4308398712A5020244649 @default.
• W4308398712 hasAuthorship W4308398712A5023821463 @default.
• W4308398712 hasAuthorship W4308398712A5033930430 @default.
• W4308398712 hasAuthorship W4308398712A5037556478 @default.
• W4308398712 hasAuthorship W4308398712A5044519846 @default.
• W4308398712 hasAuthorship W4308398712A5044693959 @default.
• W4308398712 hasAuthorship W4308398712A5054594421 @default.
• W4308398712 hasAuthorship W4308398712A5058952921 @default.
• W4308398712 hasAuthorship W4308398712A5070576137 @default.
• W4308398712 hasAuthorship W4308398712A5084572579 @default.
• W4308398712 hasAuthorship W4308398712A5084743693 @default.
• W4308398712 hasBestOaLocation W43083987121 @default.
• W4308398712 hasConcept C10882517 @default.
• W4308398712 hasConcept C129374314 @default.
• W4308398712 hasConcept C147483822 @default.
• W4308398712 hasConcept C149532602 @default.
• W4308398712 hasConcept C154317977 @default.
• W4308398712 hasConcept C202751555 @default.
• W4308398712 hasConcept C203014093 @default.
• W4308398712 hasConcept C2776090121 @default.
• W4308398712 hasConcept C2776955114 @default.
• W4308398712 hasConcept C2777701055 @default.
• W4308398712 hasConcept C2778957590 @default.
• W4308398712 hasConcept C28328180 @default.
• W4308398712 hasConcept C28651165 @default.
• W4308398712 hasConcept C3875195 @default.
• W4308398712 hasConcept C55493867 @default.
• W4308398712 hasConcept C71924100 @default.
• W4308398712 hasConcept C86803240 @default.
• W4308398712 hasConcept C8891405 @default.
• W4308398712 hasConcept C90375314 @default.
• W4308398712 hasConcept C95444343 @default.
• W4308398712 hasConceptScore W4308398712C10882517 @default.
• W4308398712 hasConceptScore W4308398712C129374314 @default.
• W4308398712 hasConceptScore W4308398712C147483822 @default.
• W4308398712 hasConceptScore W4308398712C149532602 @default.
• W4308398712 hasConceptScore W4308398712C154317977 @default.
• W4308398712 hasConceptScore W4308398712C202751555 @default.
• W4308398712 hasConceptScore W4308398712C203014093 @default.
• W4308398712 hasConceptScore W4308398712C2776090121 @default.
• W4308398712 hasConceptScore W4308398712C2776955114 @default.
• W4308398712 hasConceptScore W4308398712C2777701055 @default.
• W4308398712 hasConceptScore W4308398712C2778957590 @default.
• W4308398712 hasConceptScore W4308398712C28328180 @default.
• W4308398712 hasConceptScore W4308398712C28651165 @default.
• W4308398712 hasConceptScore W4308398712C3875195 @default.
• W4308398712 hasConceptScore W4308398712C55493867 @default.
• W4308398712 hasConceptScore W4308398712C71924100 @default.
• W4308398712 hasConceptScore W4308398712C86803240 @default.
• W4308398712 hasConceptScore W4308398712C8891405 @default.
• W4308398712 hasConceptScore W4308398712C90375314 @default.
• W4308398712 hasConceptScore W4308398712C95444343 @default.
• W4308398712 hasLocation W43083987121 @default.
• W4308398712 hasOpenAccess W4308398712 @default.
• W4308398712 hasPrimaryLocation W43083987121 @default.
• W4308398712 hasRelatedWork W2144872368 @default.
• W4308398712 hasRelatedWork W2559634303 @default.
• W4308398712 hasRelatedWork W2744371465 @default.
• W4308398712 hasRelatedWork W2750688768 @default.
• W4308398712 hasRelatedWork W2989972949 @default.
• W4308398712 hasRelatedWork W3138542324 @default.
• W4308398712 hasRelatedWork W3217235816 @default.
• W4308398712 hasRelatedWork W4307957861 @default.
• W4308398712 hasRelatedWork W4308398712 @default.
• W4308398712 hasRelatedWork W4322584302 @default.
• W4308398712 isParatext "false" @default.
• W4308398712 isRetracted "false" @default.
• W4308398712 workType "article" @default.